

# A prospective study to assess the impact and benefits of an artificial intelligence system in double reading for breast cancer screening

<b>Submission date</b> 30/08/2023	<b>Recruitment status</b> No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 29/09/2023	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
<b>Last Edited</b> 04/10/2023	<b>Condition category</b> Cancer	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

## Plain English summary of protocol

### Background and study aims

Normally, mammograms (breast X-rays) are looked at by two qualified healthcare professionals (often called 'readers'), to decide if more tests are needed. In this study, a piece of new technology using artificial intelligence (AI) software (known as 'Mia') will also look at some mammograms in the background, in addition to the two readers. The study aims to see how the AI performs when compared to readers, and the impact of introducing AI into breast screening. This will help to understand if AI might help us find more cancers and how humans may interact with AI in the real world.

### Who can participate?

Breast screening participants at Leeds Teaching Hospitals aged between 49 and 70 years old who have a standard 4-view mammogram taken of sufficient quality

### What does the study involve?

Half of eligible women (1 in 2) will be chosen at random to have their mammogram looked at by the AI, as well as two readers. The other half will have their mammogram looked at by two readers as normal. Breast screening appointments will go ahead as normal. Women will not need to have any extra X-rays, and women will find out their results in the usual way.

### What are the possible benefits and risks of participating?

The long history of breast screening shows human readers miss a very small number of breast cancers on mammograms. It is possible a small proportion of women whose cancers may have been missed by human readers will benefit from earlier cancer detection by having AI involved. This is because AI and humans do not analyse mammograms in the same way.

Using AI to look at mammograms could mean that more women are called back for further tests. This may make participants feel anxious about having further tests, but most people who need further tests will not be diagnosed with breast cancer. In the breast screening programme,

about 4 in every 100 women are asked to come back for more tests after screening. Out of these 4 women, 1 will be found to have cancer. The rest will not have cancer and will go back to having screening invitations every three years.

Where is the study run from?

Kheiron Medical Technologies (UK)

When is the study starting and how long is it expected to run for?

April 2022 to August 2024

Who is funding the study?

NHS Accelerated Access Collaborative (AAC) National Institute for Health and Care Research (NIHR) Artificial Intelligence in Health and Care Award (UK)

Who is the main contact?

Dr Annie Ng, annie@kheironmed.com (UK)

### **Study website**

<https://www.kheironmed.com/libra-study>

## **Contact information**

### **Type(s)**

Principal Investigator

### **Contact name**

Dr Nisha Sharma

### **Contact details**

Director of Breast Screening and Clinical Lead for breast imaging

Leeds Teaching Hospital NHS Trust

St James's University Hospital

Beckett Street

Leeds

United Kingdom

LS9 7TF

+44 (0)771 892 4193

Nisha.Sharma2@nhs.net

### **Type(s)**

Scientific

### **Contact name**

Dr Annie Ng

### **ORCID ID**

<http://orcid.org/0000-0002-0016-2275>

### **Contact details**

2nd Floor, Stylus Building

116 Old Street

London  
United Kingdom  
EC1V 9BG  
+44 (0)7379467701  
annie@kheironmed.com

**Type(s)**

Public

**Contact name**

Dr Annie Ng

**Contact details**

2nd Floor, Stylus Building  
116 Old Street  
London  
United Kingdom  
EC1V 9BG  
+44 (0)7379467701  
annie@kheironmed.com

## Additional identifiers

**EudraCT/CTIS number**

Nil known

**IRAS number**

316873

**ClinicalTrials.gov number**

Nil known

**Secondary identifying numbers**

KMT014, IRAS 316873, CPMS 53675

## Study information

**Scientific Title**

A prospective study to assess the impact and benefits of an AI system in double reading for breast cancer screening

**Acronym**

LIBRA: Leeds Investigation of BReast screening AI

**Study objectives**

This study aims to evaluate mammography intelligent assessment (Mia)'s influence on arbitration and the potential clinical benefit of Mia by involving Mia's opinion as a third independent read in arbitrated breast screening cases.

**Ethics approval required**

Ethics approval required

### **Ethics approval(s)**

Approved 01/11/2022, South East Scotland Research Ethics Committee 02 (2nd Floor, Waverley Gate, 2-4 Waterloo Place, Edinburgh, EH1 3EG, United Kingdom; +44 (0)131 536 9000; ruth.fraser4@nhslothian.scot.nhs.uk), ref: 22/SS/0077

### **Study design**

Prospective feasibility study

### **Primary study design**

Interventional

### **Secondary study design**

Randomised controlled trial

### **Study setting(s)**

Medical and other records

### **Study type(s)**

Diagnostic

### **Participant information sheet**

Not available in web format, please use contact details to request a participant information sheet.

### **Health condition(s) or problem(s) studied**

Breast cancer

### **Interventions**

This is a single-site prospective feasibility study comparing double reading with Mia (AI software as a medical device) with standard double reading in a local breast screening programme. The study will evaluate Mia's influence on arbitration and the potential clinical benefit of Mia by involving Mia's opinion as a third independent read in arbitrated breast screening cases. 50% of all eligible cases will be randomly assigned to Arm A, and the other 50% to Arm B to encourage the diligent reading of all cases according to the standard of care. Approximately 6876 total screens are expected to be included in the total sample size.

An active dissent approach will be used where the sample obtained is more likely to be representative of a real-world screening population and a better evaluation of the behavioural impact and benefits that Mia may have in real-world deployments in double reading. Potential participants will have multiple opportunities to learn about the study, including thorough materials that have been designed in collaboration with PPI Advisors, and will have the option to opt out of participation.

In Arm A, Mia's outputs will be shared with the human readers as part of the arbitration process. In Arm B, Mia will not analyse cases until after the positive evidence collection period is complete and these cases will be handled in a retrospective analysis. As such, Mia's outputs for control arm cases will not be available to human readers as part of the arbitration process during the study.

The following procedures will be applied for Arm A:

1. All cases will continue to be read according to the site's routine double-reading workflow. Therefore, human Readers R1 and R2 will read all cases as normal
2. Human Readers R1 and R2 will always be blinded to Mia's opinion in the study
3. Opinions for R1, R2 and Mia on eligible cases will be compared
4. When R1, R2 and Mia all agree to not recall a case, this is taken as the final recall decision and follows the routine screening pathway. Where R1, R2 and Mia all agree to recall a case, consensus arbitration takes place. When there is a disagreement between any of the readers, where any but not all of the readers (R1, R2, or Mia) decide to call back a case, discordant arbitration takes place.
5. All cases to be arbitrated will continue to be arbitrated according to the site's local standard operating practice and will include R1, R2 and Mia opinions
6. After arbitration, the recall or no recall decision will follow the site's standard pathway.

As illustrated by the sequence of events in the intervention arm, there is no change to the participant's visit in terms of how they receive their mammogram and their general appointment. No further visits or interventions/procedures are required.

### **Intervention Type**

Device

### **Pharmaceutical study type(s)**

Not Applicable

### **Phase**

Not Applicable

### **Drug/device/biological/vaccine name(s)**

Mammography intelligent assessment (Mia)

### **Primary outcome measure**

The absolute and relative differences in consensus between arbitration and Mia will be compared between Arm A and Arm B using readers' opinions at the end of recruitment

### **Secondary outcome measures**

All secondary outcome measures will be measured at the end of recruitment.

Measurements including consensus, discordance rate, recall rate, arbitration rate, and proportion of cases/cancers in different scenarios will use reader opinions to calculate.

Measurements including cancer detection rate, sensitivity, specificity, and positive predictive value will use reader opinions and cancer follow-up information to calculate.

1. Clinical metrics including recall rate, cancer detection rate, sensitivity, specificity, and positive predictive value will be measured for each reader
2. Discordance rate between Mia and Reader 1 to quantify potential workload saving
3. Proportion of cases and cancers in different scenarios in Arm A
4. Consensus between arbitration and each reader per scenario and across all scenarios in Arm A
5. Recall rate and cancer detection rate of arbitration per scenario in Arm A
6. Potential to reduce recall rate and increase cancer detection rate in specific scenarios in Arm A
7. Measurement comparisons between Arm A and Arm B, measuring the proportion of cases and cancers in different scenarios and consensus between arbitration and each reader in different scenarios

8. Measurements and comparisons between simulated double reading in Arm A to Arm B, measuring recall rate, arbitration rate, cancer detection rate, sensitivity, specificity, and positive predictive value
9. Simulations of the 'extra reader' workflow, measuring recall rate, cancer detection rate, sensitivity, specificity, and positive predictive value, to understand potential clinical benefits

**Overall study start date**

08/04/2022

**Completion date**

31/08/2024

## Eligibility

**Key inclusion criteria**

1. Participants routinely invited or self-referred for breast screening
2. Participants identified as female
3. Participants for whom a 2D FFDM standard four-view mammography examination was acquired

**Participant type(s)**

Service user

**Age group**

Mixed

**Lower age limit**

49 Years

**Upper age limit**

70 Years

**Sex**

Female

**Target number of participants**

1320 arbitrated cases (estimated to result in about 6876 participants)

**Key exclusion criteria**

1. Patients with cosmetic breast implants
2. Very high risk patients, including genetic abnormalities etc.
3. Patients who have actively dissented from participation in the study
4. Cases marked as technical recall

**Date of first enrolment**

31/10/2023

**Date of final enrolment**

29/02/2024

# Locations

## Countries of recruitment

England

United Kingdom

## Study participating centre

**Leeds Teaching Hospitals NHS Trust**

St. James's University Hospital

Beckett Street

Leeds

United Kingdom

LS9 7TF

# Sponsor information

## Organisation

Kheiron Medical Technologies (United Kingdom)

## Sponsor details

Stylus Building

116 Old Street

London

England

United Kingdom

EC1V 9BG

None available

science@kheironmed.com

## Sponsor type

Industry

## Website

<https://www.kheironmed.com/>

## ROR

<https://ror.org/01r3ct535>

# Funder(s)

## Funder type

Government

**Funder Name**

NHS AAC NIHR AI in Health and Social Care Award

## **Results and Publications**

**Publication and dissemination plan**

Planned publication in a high-impact peer-reviewed journal

**Intention to publish date**

31/08/2025

**Individual participant data (IPD) sharing plan**

The data-sharing plans for the current study are unknown and will be made available at a later date.

**IPD sharing plan summary**

Data sharing statement to be made available at a later date